Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an international, prospective, multicenter, non-randomized observational study to confirm the safety and performance of the cervical disc prosthesis MOVE4-C. The study also aims to understand how patients quality of life changes after implantation and to assess the range of motion, which is important for implants that preserve movement. This research focuses on individuals with discopathy, herniated cervical discs, spinal stenoses, or radiculopathy. The study involves a single group of 170 patients who will receive a mono- or bisegmental implantation of the MOVE4-C cervical prosthesis. This device-based intervention is observed without randomization or a comparison group. The research collects clinical and radiological data to evaluate the devices performance over time. There are no placebo or blinded treatments involved. Participants will be followed up from baseline through 24 months after implantation. Researchers will assess improvements in neck disability, arm and neck pain using the Neck Disability Index and Visual Analogue Scales, as well as other health and function measures like the Core Outcome Measure Index, SF-36, EuroQoL, and Japanese Orthopedic Association Score. Range of motion and any adverse events related to the device will be monitored. The study includes clinical visits and evaluations to collect these outcomes and ensure safety throughout the follow-up period.
Actively Recruiting
Researchers are studying patients with breast cancer, focusing on those with metastatic disease who typically have the poorest outlook. The trial aims to improve treatment decisions and quality of care by analyzing tumor characteristics. Although national guidelines recommend molecular reassessment of metastatic tumors, biopsies are rare due to invasiveness, so the study explores blood-based methods to assess tumor features and their relation to treatment outcomes and health economics. The study involves two groups about 3,500 patients with locally advanced or metastatic breast cancer receiving any line of treatment, and approximately 10,000 patients with early breast cancer undergoing neoadjuvant or adjuvant therapy regardless of regimen. Blood samples will be collected during routine blood draws to analyze tumor molecular characteristics and biomarkers for progression and survival. Participants will be followed with assessments including quality of life, therapy adherence, depression factors, and adverse events at study entry and regularly up to 60 months. The study will measure progression-free survival in metastatic breast cancer and disease-free survival in early breast cancer, along with overall survival and health economic outcomes. Results of molecular testing will be shared with patients at study end, providing comprehensive data to support improved breast cancer care.
Actively Recruiting
Researchers are conducting a prospective registry study to observe and document the treatment and disease progression in patients with recurrent and metastatic prostate cancer. The study includes four distinct patient groups based on disease status those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. Each group is enrolled and followed independently over different time periods to understand the course of therapy and disease. The study does not prescribe any specific treatment but records routine care as decided by each patients physician. Data collection occurs during routine clinical visits at set intervals, including after enrollment, every 3 to 6 months, and when therapy changes occur. Standardized quality of life questionnaires FACT-P and EQ-5D-5L are completed, and biological samples are collected to support comprehensive assessment. Participants are followed long-term, with an average follow-up of seven years. Researchers document therapy patterns, disease management strategies, imaging assessments, patient-reported outcomes, treatment adherence, and adverse events throughout this period. The focus is on real-world data reflecting everyday clinical practice, enabling a detailed understanding of treatment effectiveness and disease progression in prostate cancer patients.
Actively Recruiting
Ulcerative colitis UC is an inflammatory bowel disease causing inflammation and bleeding in the rectum and colon. This study evaluates the change in disease activity in adult participants with moderate to severe UC who are treated with risankizumab in real-world clinical practice. The study is observational and will include about 200 participants across multiple sites in Germany and Austria. Participants will receive risankizumab as prescribed by their physicians according to routine clinical care and local guidelines. The treatment is not assigned by the study team but follows the physicians decision. Participants will be observed and followed for up to 52 weeks while receiving this treatment under normal clinical conditions. During the study, participants will attend regular visits at hospitals or clinics as part of their routine care. There will be no additional burden beyond regular clinical visits. Researchers will measure the percentage of participants achieving symptomatic remission based on the Partial Adapted Mayo Score over approximately 52 weeks. Safety and effectiveness of risankizumab will be monitored throughout the study period.